StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The significant clinical benefits and upcoming FDA submission enhance investor confidence in COGT, akin to past biotech success stories such as Amgen’s AVA trial, which similarly boosted market perception and stock prices.
What happened, with direct paths to the underlying reporting
Cogent's stock surged 124% to $33.20 on high trading volume. Phase 3 trial showed bezuclastinib improved survival rates in GIST. Combination therapy reached median PFS of 16.5 months, significantly better than sunitinib. COGT plans NDA submission to the FDA in early 2026. Company anticipates presenting detailed trial results at a major conference in 2026.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.